Introduction
Chronic pain affects an estimated 1.5 billion people worldwide, making it the leading cause of disability globally. Fibromyalgia alone affects 2–4% of the population — predominantly women — and is characterized by widespread musculoskeletal pain, fatigue, cognitive impairment ("fibro fog"), sleep disturbance, and heightened sensitivity to stimuli. Despite its prevalence, fibromyalgia remains poorly understood and inadequately treated by conventional medicine, with many patients cycling through years of misdiagnosis and ineffective treatments.
A neuroinflammatory and central sensitization framework is transforming our understanding of chronic pain and fibromyalgia — revealing not a purely psychological condition or a simple musculoskeletal disorder, but a complex neuroimmune syndrome with identifiable biological drivers that respond to targeted integrative interventions.
Part I: Understanding Chronic Pain & Central Sensitization
Acute vs. Chronic Pain
Acute pain is a protective biological signal — a warning of tissue damage that resolves as healing occurs. Chronic pain is fundamentally different: it persists beyond tissue healing, often in the absence of ongoing tissue damage, and involves pathological changes in the nervous system itself.
Central Sensitization
Central sensitization is the neurobiological process at the heart of fibromyalgia and many chronic pain conditions — the amplification of neural signaling within the CNS causing pain hypersensitivity disproportionate to peripheral input. Key features include allodynia (pain from non-painful stimuli), hyperalgesia (exaggerated pain response), temporal summation ("wind-up"), widespread pain beyond the original injury site, and cognitive and emotional amplification.
Mechanisms include NMDA receptor sensitization in the dorsal horn; reduced descending pain inhibition; microglial activation amplifying pain signaling; and neuroplastic changes in the anterior cingulate cortex, insula, and thalamus.
The Neuroinflammatory Driver
Neuroinflammation — particularly spinal cord and brain microglial activation — is a primary driver of central sensitization. Activated microglia release IL-1β, TNF-α, IL-6, and glutamate that sensitize dorsal horn neurons, lower pain thresholds, and maintain the central sensitization state. Noori et al. have reviewed the evidence for neuroinflammation in chronic pain, emphasizing that targeting microglial activation offers superior outcomes compared to peripheral analgesic approaches.
Part II: Mast Cell Activation Syndrome (MCAS)
MCAS frequently co-occurs with fibromyalgia, ME-CFS, POTS, and hypermobile Ehlers-Danlos syndrome. Mast cells — found throughout connective tissue, gut, skin, and around nerves and blood vessels — release histamine, tryptase, prostaglandins, leukotrienes, and cytokines when inappropriately activated by foods, chemicals, temperature, stress, and infections.
The mast cell-nerve interaction is bidirectional: activated mast cells release substance P and NGF sensitizing pain fibers, while activated pain fibers release neuropeptides further activating mast cells — creating a neuroimmune amplification loop perpetuating chronic pain and systemic inflammation.
Part III: Fibromyalgia — A Neuroimmune Syndrome
Fibromyalgia is best understood as a neuroimmune syndrome characterized by central sensitization; microglial neuroinflammation; HPA axis dysregulation impairing pain modulation and sleep; autonomic nervous system dysfunction with sympathetic dominance; sleep architecture disruption (reduced slow-wave sleep); gut dysbiosis amplifying neuroinflammation via the gut-brain axis; Clinical Endocannabinoid Deficiency (CECD) impairing the ECS's pain-modulating functions; and mitochondrial dysfunction in muscle and neural tissue (Seyfried et al.). Seyyedabadi et al. have highlighted the IL-6/STAT3 axis as a driver of neuroinflammation in fibromyalgia, with elevated IL-6 correlating with pain severity and fatigue scores.
Part IV: Related Chronic Pain Conditions
ME-CFS shares significant overlap with fibromyalgia — profound fatigue, post-exertional malaise, cognitive impairment, pain, and autonomic dysfunction — with neuroinflammation, mitochondrial dysfunction, and persistent viral triggers (EBV, HHV-6) as central mechanisms. CRPS involves neuroinflammation, central sensitization, and mast cell activation following injury. Migraine is a neuroinflammatory condition involving cortical spreading depression, trigeminal activation, CGRP-driven neurogenic inflammation, and CECD. IBS co-occurs frequently with fibromyalgia, sharing visceral hypersensitivity driven by gut dysbiosis and mast cell activation in the intestinal mucosa.
Part V: Integrative Approaches
Low Dose Naltrexone (LDN)
LDN is the most evidence-backed integrative agent for fibromyalgia. TLR4 antagonism suppresses microglial activation — the primary driver of central sensitization; endorphin upregulation enhances descending pain inhibition; TNF-α and IL-6 reduction addresses neuroinflammatory pain maintenance. Cairns et al. have documented LDN's efficacy in fibromyalgia with significant reductions in pain, fatigue, and cognitive symptoms in clinical trials.
CBD & THC
CECD is strongly implicated in fibromyalgia, making ECS restoration foundational. CBD provides FAAH inhibition increasing anandamide; TRPV1 activation reducing peripheral sensitization; CB2-mediated microglial suppression; and 5-HT1A activation improving sleep and anxiety. THC provides CB1-mediated pain reduction, muscle relaxation, and sleep improvement. A 1:1 CBD:THC ratio is commonly used, with higher CBD ratios for daytime use. See our Buyer's Guide to CBD & THC Oils for practical guidance.
DMSO
DMSO's analgesic, anti-inflammatory, and membrane-penetrating properties make it particularly valuable in chronic pain. Topically, it penetrates deeply into musculoskeletal tissue reducing local inflammation. Systemically, free radical scavenging reduces neuroinflammatory oxidative stress. Cairns et al. have noted DMSO's underutilized potential in neuroinflammatory chronic pain.
Mast Cell Stabilization
- Quercetin (500–1000mg/day) — most potent natural mast cell stabilizer; inhibits degranulation, histamine release, and prostaglandin production
- PEA (600–1200mg/day) — endogenous mast cell modulator via PPAR-α; reduces mast cell-nerve interaction; strong clinical evidence in fibromyalgia
- Vitamin C (2–4g/day) — degrades histamine, supports mast cell stability
- Luteolin — potent mast cell stabilizing and anti-neuroinflammatory flavonoid
- Low-histamine diet — reduces mast cell trigger burden
Botanical & Nutritional Agents
- Curcumin — reduces microglial activation, COX-2, and substance P; clinical evidence in fibromyalgia
- Boswellia (AKBA) — 5-LOX inhibition reducing leukotriene-driven neuroinflammation
- Magnesium glycinate (400–600mg/day) — NMDA receptor antagonism reducing central sensitization; deficiency common in fibromyalgia
- ALA (600mg/day) — mitochondrial antioxidant; clinical evidence in neuropathic pain
- Omega-3 (3–4g EPA+DHA/day) — reduces neuroinflammation and prostaglandin-driven sensitization
- Melatonin (3–10mg at night) — improves sleep architecture; direct analgesic effects in fibromyalgia trials
- 5-HTP (100–300mg/day) — serotonin precursor supporting descending pain inhibition
- D-Ribose (5g 3x/day) — mitochondrial energy substrate; clinical evidence in fibromyalgia and ME-CFS
Mind-Body & Lifestyle
- Mindfulness-based stress reduction (MBSR) — reduces pain catastrophizing and central sensitization
- Gentle movement — yoga, tai chi, aquatic therapy; reduces central sensitization without exacerbating ME-CFS
- Sleep optimization — foundational; poor sleep worsens central sensitization
- Vagal nerve activation — breathing exercises, cold exposure, humming reduce sympathetic dominance and neuroinflammation
- Gut restoration — probiotics, L-glutamine, gut-brain axis support
Integrative Protocol Summary
- LDN (1.5–4.5mg/day) — microglial suppression, endorphin upregulation
- PEA (600–1200mg/day) — mast cell modulation, neuroinflammation
- CBD (50–150mg/day) + THC (condition-dependent) — ECS restoration, pain, sleep
- Quercetin (500–1000mg/day) — mast cell stabilization
- Magnesium glycinate (400–600mg/day) — NMDA antagonism
- Curcumin (500–1000mg/day enhanced) — microglial suppression
- Omega-3 (3–4g/day) — neuroinflammation reduction
- Melatonin (3–10mg at night) — sleep, analgesia
- ALA (600mg/day) — mitochondrial antioxidant
- DMSO — topical and/or systemic anti-inflammatory
- Gut restoration + mind-body practices
This article is for educational purposes only and does not constitute medical advice.
Key References
- Cairns, D.M. et al. — LDN in fibromyalgia and central sensitization syndromes.
- Noori, S. et al. — Neuroinflammation in chronic pain: natural therapeutic approaches.
- Seyyedabadi, B. et al. — IL-6/STAT3 neuroinflammatory signaling in fibromyalgia.
- Seyfried, T.N. et al. — Mitochondrial dysfunction in chronic pain and fatigue syndromes.
- Andries, K. et al. — Gut-brain axis in fibromyalgia and chronic pain conditions.
0 comments